Back to Basics – Examining Mechanisms of New IBD Therapies

CMEO Medical Meeting

Symposium Date: Friday, January 20, 2023
12:15 PM - 1:45 PM MT
Gaylord Rockies Resort & Convention Center
Room: AURORA D
Denver, CO

This activity offers CE credit for:

  1. ABIM (MOC)
  2. Medicine (accme)
  3. Nursing (ANCC)
  4. Pharmacy (acpe)
  5. PA (aapa)
  6. Other


All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Saturday, January 20, 2024
Note: Credit Is No Longer Available

Faculty


Marla C. Dubinsky, MD
Marla C. Dubinsky, MD (Moderator)
Professor of Pediatrics and Medicine
Division Chief, Pediatric Gastroenterology and Nutrition
Co-Director Susan and Leonard Feinstein IBD Clinical Center
Icahn School of Medicine at Mount Sinai
New York, NY

Sara Horst, MD, MPH
Sara Horst, MD, MPH 
Associate Professor, Gastroenterology, Hepatology, & Nutrition
Vanderbilt University Medical Center
Nashville, TN

Gil Y. Melmed, MD, MS
Gil Y. Melmed, MD, MS 
Professor of Medicine
Director of IBD Clinical Research
Associate Director of Gastroenterology and Hepatology
Cedars-Sinai
Los Angeles, CA

Statement of Need

Since their introduction over 2 decades ago, anti–tumor necrosis factor (-TNF) agents have become frequently utilized as first-line biologic treatments for inflammatory bowel disease (IBD). Unfortunately, up to two-thirds of patients with IBD either do not respond to anti-TNF therapy or lose response within a year of starting treatment. More recently developed biologics such as interleukin (IL) inhibitors, (e.g., IL-23, IL-12/-23) have demonstrated effectiveness in achieving both short- and long-term treatment targets of symptom control and mucosal healing in patients with IBD.

This CME Outfitters symposium will feature Drs. Dubinsky, Horst, and Melmed in an expert panel discussion focusing on strategies for the treatment of both biologic-naïve and biologic- experienced patients with IBD; incorporating comparative efficacy and safety data for IL-23 and IL-12/23 inhibitors into the development of treatment plans; and utilizing an interprofessional team to improve patient care and treatment outcomes.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Incorporate evidence-based clinical, biomarker, and endoscopic treatment targets into clinical practice when developing treatment goals for patients with IBD.
  • Develop treatment plans based on comparative efficacy and safety data for biologic-naïve and biologic-experienced patients with IBD.
  • Engage an interprofessional team to improve patient care and IBD treatment outcomes.

Financial Support

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Target Audience

Physicians, nurse practitioners, PAs, nurses, and pharmacists specializing in gastroenterology and surgery as well as psychiatry and primary care.

Credit Information

Jointly Accredited Provider
JA

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



CME Credit (Physicians):
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AGA Institute designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians (ACCME):
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AGA Institute designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC):
This activity is designated for 1.5 contact hours.

California Residents:
This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC’s provider number is CEP15510.

Pharmacists (ACPE):
This application-based activity is approved for 1.5 contact hours (0.15 CEUs) of continuing pharmacy credit (JA0007185-0000-23-008-L01-P).

PAs (AAPA):
AAPA CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

AGA Disclosure Statement:
In accordance with the ACCME’s Standards for Integrity and Independence, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The AGA Institute implements a mechanism to identify and mitigate all conflicts of interest prior to delivering the educational activity to learners.

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Dubinsky reports the following financial relationships:

Advisory Board: AbbVie Inc.; Bristol Myers Squibb Company; Eli Lilly and Company; Janssen Biotech, Inc.; Pfizer Inc.; Prometheus Biosciences; and Prometheus Laboratories

Consultant: AbbVie Inc.; Arena Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; Gilead Sciences, Inc.; Janssen Biotech, Inc.; Pfizer Inc; Prometheus Biosciences; Prometheus Laboratories; and Takeda

Grants: AbbVie Inc. and Janssen Biotech, Inc.

Research Support: Prometheus Laboratories

Stock Shareholder (ownership interest): Trellus Health Inc.

Dr. Horst reports the following financial relationships:

Consultant: AbbVie Inc.; Janssen Biotech, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.

Dr. Melmed reports the following financial relationships:

Advisory Board: AbbVie Inc.; Arena Pharmaceuticals, Inc.; Boehringer-Ingelheim; Bristol Meyers Squibb Company/Celgene Corporation; Entasis Therapeutics; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Biotech, Inc.; Medtronic; Pfizer Inc.; Prometheus Laboratories; Samsung Bioepis; Takeda Pharmaceuticals U.S.A., Inc.; and TECHLAB, Inc.

Consultant: AbbVie Inc; Arena Pharmaceuticals, Inc.; Boehringer-Ingelheim; Bristol Meyers Squibb Company/Celgene Corporation; Dieta; Entasis Therapeutics; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Biotech, Inc.; Medtronic; Nephroceuticals, LLC; Oshi Health, Inc.; Pfizer Inc.; Prometheus Laboratories; Samsung Bioepis; Takeda Pharmaceuticals U.S.A., Inc.; and TECHLAB, Inc.

Grants: Pfizer Inc.

The following peer reviewer and CME Outfitters staff have no financial relationships:

  • Shirley Michelle Franks, MSN, APRN, FNP-BC (peer reviewer)
  • Susan Perry (planning committee)
  • Kasey Brandt, PharmD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)


  • Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


    This document was last modified on:

    MM-130-012023-01